The role of blood platelets in coronary atherosclerosis and thrombosis

REFERENCES

• Ross R, Faggiotto A, Bowen-Pope D, Raines E. The role of endothelial injury and platelet and macrophage interactions in atherosclerosis. Cir-culation 1983; 70 Suppl III: 77–82.
   Google Scholar
• Conti CR, Metha JL. Acute myocardial ischemia: role of atherosclerosis, thrombosis, platelet acti-vation, coronary vasospasm, and altered arachi-donic acid metabolism. Circulation 1987; 75 Suppl V: 84–95.
   Google Scholar
• Aviram M, Brook JG. Platelet activation by plasma proteins. Progr Cardiovasc Dis 1987; 30: 61–76.
   PubMed Web of Science ®Google Scholar
• Sevitt S. Platelet and foam cells in the evolution of atherosclerosis. Histological and immunohisto-logical studies in human lesions. Atherosclerosis 1986; 61: 107–15.
   Google Scholar
• Davies MJ, Woolf N, Bowles PM, Pepper J. Morphology of the endothelium over athero-sclerotic plaques in human coronary arteries. Br Heart J 1988; 60: 459–64.
   PubMedGoogle Scholar
• Curtiss LK, Black AS, Takagi Y, Plow EF. New mechanism for foam cell generation in athero-sclerotic lesions. J Chin Invest 1987; 80: 367–73.
   PubMed Web of Science ®Google Scholar
• Takagi Y, Dyer CD, Curtiss LK. Platelet-enhanced apolipoprotein E production by human macro-phages: a possible role in atherosclerosis. J Lipid Res 1988; 29: 858–67.
   Google Scholar
• Mendelsohn ME, Loscalzo J. Role of platelets in cholesteryl formation by U-937 cells. J Clin Invest 1988; 81: 62–8.
   PubMedGoogle Scholar
• Maor I, Brook GJ, Aviram M. Platelet secreted lipoprotein-like particle is taken up by the macro-phage scavanger receptor and enhances cellular cholesterol accumulation. Atherosclerosis 1991; 88: 163–74.
   Google Scholar
• Fuhrman B, Brook GJ, Aviram M. Proteins derived from platelet a-granules modulate the uptake of oxidized low density lipoprotein by macrophages. Biochim Biophys Acta 1992; 1127: 15–21.
   Google Scholar
• Fuhrmann B, Brook GJ, Aviram M. Activated platelets secrete a protein-like factor that stimu-lates oxidized-LDL receptor activity in macro-phages. J Lipid Res 1991; 32: 1113–23.
   Google Scholar
• Andrews HE, Aitken JW, Hassal DG, Skinner VO, Bruckdorfer KR. Intracellular mechanisms in the activation of human platelets by low-density lipo-proteins. Biochem J 1989; 242: 559–64.
   Google Scholar
• Ardlie NG, Selley ML, Simons LA. Platelet activation by oxidatively modified low density lipoproteins. Atherosclerosis 1989; 76: 117–24.
   Google Scholar
• Naseem KM, Goodall AH, Bruckdorfer KR. Differential effects of native and oxidatively modified low-density lipoproteins on platelet function. Platelets 1997; 8: 163–73.
   Google Scholar
• Saniabadi AR, Umemura K, Shimoyama M, Adachi M, Nakano M, Nakashima M. Aggre-gation of human blood platelets by remnant like lipoprotein particles of plasma chylomicrons and very low density lipoproteins. Thromb Hemostas 1997; 77: 996-1001.81.
   Google Scholar
• Pfenning 0, Zhao B, Frye S, Dierichs R. High-density lipoprotein fails to inhibit serotonin-induced activation of blood platelets. Am J Hematol 1995; 50: 307–9.
   Google Scholar
• Nofer JR, Tepel M, Kehrel B, Wierville S, Water M, Sedorf U, et al. Low-density lipoproteins inhibit the Na+/H+ antiport in human platelets: a novel mechanism enhancing platelet activity in hyper-cholesterolaemia Circulation 1997; 95: 1370–7.
   Google Scholar
• Gorog P, Kovacs IB. Lipid peroxidation by acti-vated platelets: A possible link between throm-bosis and atherogenesis. Atherosclerosis 1995; 115: 121–8.
   PubMed Web of Science ®Google Scholar
• Farstad M, Bakken AM, Berge RK. The activity and subcellular distribution of the peroxisomal enzyme acyl-CoA oxidase in human blood plate-lets. Biochem J 1992; 286: 829–31.
   Google Scholar
• Harker LA, Ross R, Slichter SJ, Scott CR. Homocysteine-induced arteriosclerosis. The role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976; 58: 731–41.
   PubMed Web of Science ®Google Scholar
• Harker LA, Harlan JM, Ross R. Effect of sulfin-pyrazone on homocysteine-induced endothelial injury and arteriosclerosis in baboons. Circ Res 1983; 53: 731–9.
   Google Scholar
• Lentz SR, Sobey CG, Piegors DJ, Bhopatkar MY, Faraci FM, Malinow MR, Heistad DD. Vascular dysfunction in monkeys with diet-induced hyper-homocyst(e)inemia. J Clin Invest 1996; 98: 24–9.
   Google Scholar
• De Clerk F, Symoens J, Janssen PAJ. Vascular protection by ketanserin, a 5-HT2 serotonergic receptor antagonist? Platelets 1991; 2: 163–6.
   Google Scholar
• Kishi Y, Numano F. In vitro study of vascular endothelial injury by activated platelets and its prevention. Atherosclerosis 1989; 76: 95–101.
   PubMedGoogle Scholar
• Jdrgensen L, Grothe AG, Larsen T, Kinlough-Rathbone, Mustard JF. Injury to cultured endo-thelial cells by thrombin-stimulated platelets. Lab Invest 1986; 54: 408–15.
   Google Scholar
• Hervig T, Farstad M. Human blood platelet serotonin studied in vitro: endogenous serotonin may stimulate thrombin-induced serotonin rel-ease in stored platelets. Platelets 1996; 7: 53–7.
   PubMed Web of Science ®Google Scholar
• Belcher PR, Drake-Holland AJ, Noble MIM. Antagonism of the platelet 5-HT2 receptor in the presence of thrombolysis. Int J Cardiol 1994; 43: 11–20.
   PubMedGoogle Scholar
• Box WA, Renzenbrink GJ, van den Linden EA, Zijlstra FJ, van Heuven-Nolsen D, Fekkes D, et al. Low-dose aspirin inhibits platelet-induced contraction of the human isolated coronary ar-tery. Circulation 1994; 89: 623–9.
   Google Scholar
• Miyazono K, Okabe T, Urabe A, Yamanaka M, Takaku F. A platelet factor that stimulate pro-liferation of vascular endothelial cells. Biochem Biophys Res Comm 1985; 126: 83–8.
   PubMedGoogle Scholar
• Ross R, Glomset JA, Kariya B, Harker L. A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. Proc Natl Acad Sci USA 1974; 71: 1207–10.
   PubMed Web of Science ®Google Scholar
• Ross R, Masuda J, Raines EW. Cellular inter-actions, growth factors and smooth muscle pro-liferation in atherogenesis. Ann NY Acad Sci 1990; 598: 102–12.
   Google Scholar
• Nemecek GM, Coughlin SR, Handley DA, Moskowitz MA. Stimulation of aortic smooth muscle cell mitogenesis by serotonin. Proc Natl Acad Sci USA 1986; 83: 674–8.
   PubMed Web of Science ®Google Scholar
• Hoyer D, Middlemiss DN. Species differences in the pharmacology of terminal 5-HT receptors in mammalian brain. Trends Pharmacol Sci 1989; 10: 130–2.
   PubMed Web of Science ®Google Scholar
• Seuwen K, Pouyssegur J. Serotonin as a growth factor. Biochem Pharmacol 1990; 39: 985–90.
   PubMed Web of Science ®Google Scholar
• Bath PMW, Martin JF. Serum platelet-derived factor and endothelin concentrations in human hypercholesterolemia. J Intern Med 1991; 230: 313–7.
   PubMedGoogle Scholar
• Araki S, Kawahara Y, Fukuzaki H, Takai Y. Serotonin plays a major role in serum-induced phopholipase C-mediated hydrolysis of phospho-inositides and DNA synthesis in vascular smooth cells. Atherosclerosis 1990; 83: 29–34.
   PubMed Web of Science ®Google Scholar
• Tamura K, Kanzaki T, Saito Yu, Otabe M, Saito Ya, Morisaki N. Serotonin (5-hydroxytryptamine, 5-HT) enhances migration of rat aortic smooth muscle cells through 5-HT2 receptors. Athero-sclerosis 1997; 132: 139–43.
   PubMed Web of Science ®Google Scholar
• Marcus AJ, Ullman HL, Safier LB. Lipid com-position of subcellular particles of human blood platelets. J Lipid Res 1969; 10: 108–14.
   Google Scholar
• Masuda M, Kudo I, Naito M, Mizushima H, Inoue K. Phospholipid composition of rat mega-karyocytes and its rearrangements in platelets. Biochim Biophys Acta 1991; 1083: 235–42.
   PubMedGoogle Scholar
• Deykin D, Desser RK. The incorporation of acetate and palmitate into lipids by human plate-lets. J Clin Invest 1968; 47: 1590–602.
   PubMed Web of Science ®Google Scholar
• Spector AA, Hoak JC, Warner ED, Fry GL. Utilization of long-chain fatty acids by human platelets. J Clin Invest 1970; 49: 1489–96.
   PubMed Web of Science ®Google Scholar
• Cohen P, Derksen A, van den Bosch H. Pathways of fatty acid metabolism in human platelets. J Chin Invest 1970; 49: 128–39.
   Google Scholar
• Zhu B, Sievers RE, Sun Y, Morse-Fisher N, Parmley WW, Wolfe CL. Is the reduction of myocardial infarct size by dietary fish oil the result of altered platelet function? Am Heart J 1994; 127: 744–55.
   Google Scholar
• Farstad M, Sander J. The existence of a long-chain acyl-CoA synthetase in homogenates of human blood platelets. Scand J Clin Lab Invest 1971; 28: 261–5.
   PubMed Web of Science ®Google Scholar
• Berge RK, Vollset SE, Farstad M. Intracellular localization of palmitoyl-CoA hydrolase and palmitoyl-CoA synthetase in human blood plate-lets and liver. Scand J Clin Lab Invest 1980; 40: 271–8.
   Google Scholar
• Bakken AM, Farstad M. Identical subcellular distribution of palmitoyl-CoA and arachidonoyl-CoA synthetase in human blood platelets. Biochem J 1989; 261: 71–6.
   PubMed Web of Science ®Google Scholar
• Wilson DB, Prescott SM, Majerus PW. Discovery of an arachidonoyl-CoA synthetase in human platelets. J Biol Chem 1982; 257: 3510–5.
   Google Scholar
• Bakken AM, Farstad M, Holmsen H. Identity bet-ween palmitoyl-CoA synthetase and arachidonoyl-CoA synthetase in human platelets? Biochem J 1991; 274: 145–52.
   Google Scholar
• Ingebretsen OC, Bakken AM, Farstad M. The content of coenzyme A, acetyl-CoA and long-chain acyl-CoA in human blood platelets. Clin Chim Acta 1982; 126: 307–13.
   Google Scholar
• McKean ML, Smith JB, Silver MJ. Phospholipid synthesis in human platelets. Formation of phosphatidylcholine from 1-acyl lysophospha-tidyl choline by acyl-CoA: 1-acyl-sn-glycero-3-phosphocholine acyltransferase. J Biol Chem 1982; 257: 11278–83.
   Google Scholar
• McKean ML, Smith JB, Silver MJ. Formation of lysophosphatidylcholine by human platelets in res-ponse to thrombin. J Biol Chem 1981; 256: 1522–4.
   Google Scholar
• Bakken AM, Farstad M. The activities of acyl-CoA: 1-acyl-lysophospholipid acyl transferase(s) in human platelets. Biochem J 1992; 288: 763–70.
   PubMed Web of Science ®Google Scholar
• Bakken AM, Farstad M, Osmundsen H. The activities of acyl-CoA hydrolase in lysate and subcellular fractions of human blood platelets in relation to activities of acyl-CoA: 1-acyl-lysophospholipid acyltransferase. Biochim Biophys Acta 1994; 1214: 180–96.
   Google Scholar
• Bang HO, Dyerberg J, Nielsen AB. Plasma lipids and lipoprotein pattern in Greenlandic west-coast eskimos. Lancet 1971 (I): 1143–6.
   Google Scholar
• Bang HO, Dyerberg J. Plasma lipids and lipo-proteins in west coast eskimos. Acta Med Scand 1972; 192: 85–94.
   PubMed Web of Science ®Google Scholar
• Dyerberg J, Bang HO, Stoffersen E, Moncada S, Vane JR. Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis? Lancet 1978 (II): 117–9.
   Google Scholar
• Bakken AM, Farstad M, Holmsen H. Fatty acids in human platelets and plasma. Fish oils decrease sensitivity towards N2 microbubbles. J Appl Physiol 1991; 70: 2669–72.
   Google Scholar
• Bakken AM, Hervig T, Thorsen T, Holmsen H. Fatty acids in human platelets and plasma. Dietary seal oil decreases sensitivity toward microbubbles. Platelets 1995; 5: 259–64.
   Google Scholar
• Malmgren R, Thorsen T, Nordvik A, Holmsen H. Microbubble-induced phospholipase C activation does not correlate with platelet aggregation. Thromb Hemostas 1993; 69: 394–6.
   PubMedGoogle Scholar
• Fischer S, von Schacy C, Siess W, Strasser T, Weber PC. Uptake, release and metabolism of docosahexaenoic acid (C22: 66)3) in human platelets and neutrophils. Biochem Biophys Res Comm 1984; 120: 907–18.
   PubMedGoogle Scholar
• Mahadevappa VG, Holub BJ. The molecular species composition of individual diacyl phospho-lipids in human platelets. Biochim Biophys Acta 1982; 713: 73–9.
   PubMed Web of Science ®Google Scholar
• Maidment CGH, Jones SP, Lea EJA. Changes in platelet membrane fatty acids after myocardial infarction. Atherosclerosis 1988; 74: 9–14.
   Google Scholar
• Boberg M, Vessby B, Croon LB. Fatty acid composition of platelet and of plasma lipid esters in relation to platelet function in patients with ischemic heart disease. Atherosclerosis 1985; 58: 49–63.
   Google Scholar
• Renaud S, Morazin R, Godsey F, Dumont E, Thevenon C, Martin JL, Mendy F. Nutrients, platelet function and composition in nine groups of French and British farmers. Atherosclerosis 1986; 60: 37–48.
   Google Scholar
• Roberts TL, Wood DA, Rimersma RA, Gallaher PJ, Lampe FC. Linoleic acid and risk of sudden death. Br Heart J 1993; 70: 524–9.
   PubMedGoogle Scholar
• Renaud S, de Backer G, Thevenon C, Joossens JV, Vermylens J, Kornitzer M, Verstraete M. Platelet fatty acids and function in two distinct regions of Belgium: relationship to age and dietary habits. J Intern Med 1991; 229: 79–88.
   PubMedGoogle Scholar
• Simonsen T, Vârtun A, Lyngmo V, Norddy A. Coronary heart disease, serum lipids, platelets and dietary fish in two communities in Northern Norway. Acta Med Scand 1987; 222: 237–45.
   PubMed Web of Science ®Google Scholar
• Owens MR, Cave WT. Dietary fish lipids do not diminish platelet adhesion to subendothelium. Br J Hematol 1990; 75: 82–5.
   PubMedGoogle Scholar
• Petroni A, Blasevich M, Salami M, Papini N, Montedoro G, Galli C. Inhibition of platelet aggregation and eicosanoid production by pheno-lic components of olive oil. Thromb Res 1995; 78: 151–60.
   PubMed Web of Science ®Google Scholar
• Mori TA, Vandongen R, Mahanian F, Douglas A. Plasma lipid levels and platelet and neutrophil function in patients with vascular disease following fish oil and olive oil supplementation. Metabolism 1992; 41: 1059–67.
   PubMedGoogle Scholar
• Schick PK, Wojenski CM, Walker J. The effects of olive oil, hydrogenated palm oil, and 6)-3 fatty acid-enriched diets on megakaryocytes and plate-lets. Atheroscler Thromb 1993; 13: 84–9.
   Google Scholar
• Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors Br Med J 1988; 296: 313–6.
   PubMed Web of Science ®Google Scholar
• Physicians health study research group. Final report on the aspirin component of the ongoing physicians health. N Engl J Med 1989; 321: 129–35.
   PubMedGoogle Scholar
• Antiplatelet trialists' collaboration. Secondary prevention of vascular disease by prolonged anti-platelet treatment. Br Med J 1988; 296: 320–31.
   Google Scholar
• Underwood MJ, More RS. The aspirin papers (Leading article). Br Med J 1994; 308: 71–2.
   PubMed Web of Science ®Google Scholar
• Weber PC. Clinical studies on the effect of n-3 fatty acids on the cell eicosanoids in the cardio-vascular system. J Int Med 1989; 225 Suppl I: 61–8.
   Google Scholar
• Apitz-Castro R, Badimon JJ, Badimon L. Effect of ajouene, the major antiplatelet compound from garlic, on platelet thrombus formation. Thromb Res 1992; 68: 145–55.
   Google Scholar
• Stein B, Fuster V. Role of platelet inhibitor therapy in myocardial infarction. Cardiovasc Drug Therapy 1989; 3: 797–813.
   PubMedGoogle Scholar
• Aviram M. LDL-platelet interaction under oxida-tive stress induces macrophage foam cell forma-tion. Thromb Hemostas 1995; 74: 560–4.
   PubMedGoogle Scholar
• Aviram M. Modified forms of low density lipo-proteins affect platelet aggregation in vitro. Thromb Res 1989; 53: 561–7.
   PubMed Web of Science ®Google Scholar
• Zhao B, Dierichs R, Liu B, Berkes P. Gold-labelled low density lipoproteins bind to washed human platelets. Platelets 1994; 5: 113–20.
   PubMed Web of Science ®Google Scholar
• Kristensen SD, Martin JF. Platelet heterogeneity and coronary artery thrombosis. Platelets 1991; 2: 11–7.
   PubMedGoogle Scholar
• Howard HHO, Hughes WE, Schaffer SW, Longenecker GL, Glenn TM. Platelet serotonin uptake during myocardial infarction. Am Heart J 1983; 106: 1077–81.
   Google Scholar
• Davies MJ, Thomas A. Thrombosis and acute coronary artery lesions in sudden cardiac ischemia death. N Engl J Med 1984; 310: 1137–40.
   PubMed Web of Science ®Google Scholar
• Davies MJ, Bland JM, Hangartner JR, Thomas AC. Factors influencing the presence or absence of acute coronary artery thrombi in sudden ischemic death. Eur Heart J 1989; 10: 203–8.
   PubMed Web of Science ®Google Scholar
• Bolli R, Ware JA, Brandon RA. Platelet-mediated thrombosis in stenosed canine arteries: inhibition by nicergoline, a platelet-active a-adrenergic antagonist. Am J Coll Cardiol 1984; 3: 1417–23.
   Google Scholar
• Golino P, Piscione F, Benedict CR, et al. Local effects of serotonin released during angioplasty. N Eng J Med 1994; 330: 523–8.
   PubMed Web of Science ®Google Scholar
• Nurden AT, Macchi L, Bihour C, Durrieu C, Besse P, Nurden P. Markers of platelet activation in coronary heart disease. Eur J Clin Invest 1994; 24 Suppl 1M: 42–45.
   Google Scholar
• Topol EJ, Califf RM, Wisman HF, et al. Rando-mised trial of coronary intervention with anti-body against platelet Ith/IIIa integrin for reduc-tion of clinical restenosis: results at six months. Lancet 1994; 343: 881–6.
   PubMed Web of Science ®Google Scholar
• The EPIC Investigators. Us of a monoclonal antibody directed against the platelet glyco-protein Ith/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956–61.
   PubMed Web of Science ®Google Scholar
• Yarnell JWG, Sweetnam PM, Elwood PC, Eastham R, Gilmour RA, O'Brien JR, Etherington MD. The haemostatic factors and ischemic heart disease (The Caerphilli study). Br Heart J 1985; 53: 483–7.
   Google Scholar
• Thaulow E, Eriksen J, Sandvik L, Stormorken H, Cohn PF. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation 1991; 84: 613–7.
   Google Scholar
• Chesebro JH, Badimon L, Fuster V. New appro-aches to treatment of myocardial infarction. Am J Cardiol 1990; 65: C12—C19.
   Google Scholar
• Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekekens CH. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973–9.
   Google Scholar
• Antiplatelet Trialists Collaboration. Collabo-rative overview of randomised trials of antiplate-let therapy—I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81–106.
   PubMed Web of Science ®Google Scholar
• Schoemig A, Neeuman FJ, Kastrali A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary artery stents. New Engl J Med 1996; 334: 1084–9.
   PubMed Web of Science ®Google Scholar
• Belch JJF. Platelets and oxygen free radicals. Platelets 1991; 3: 175–80.
   Google Scholar
• Flores NA, Sheridan DJ. The pathophysiological role of platelets during myocardial ischemia. Cardiovasc Res 1994; 28: 295–302.
   PubMed Web of Science ®Google Scholar
• Trip MD, Cats VM, van Capele FJL, Vreeken J. Platelet hyperreactivity and prognosis in sur-vivors of myocardial infarction. New Engl J Med 1990; 322: 1549–54.
   PubMed Web of Science ®Google Scholar
• Malinow MR. Homocyst(e)ine and arterial occlu-sive diseases. J Intern Med 1994; 236: 603–17.
   PubMed Web of Science ®Google Scholar
• Malinow MR, Ducimetiere P, Luc G, Evans AE, Arveiler D, Cambien F, Upson BM. Plasma homocyst(e)ine levels and graded risk for myo-cardial infarction: findings in two populations at contrasting risk for coronary heart disease. Atherosclerosis 1996; 126: 27–34.
   Google Scholar
• Nygdrd 0, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homo-cysteine levels and mortality in patients with coronary artery disease. New Engl J Med 1997; 337: 230–6.
   Google Scholar
• Stamler JS, Osborne JA, Jaraki 0, Rabbani LE, Mullins M, Singel D, Loscalzo J. Adverse vas-cular effects of homocysteine are modulated by endothelium-derived relaxing factor and rel-ated oxides of nitrogen. J Clin Invest 1993; 91: 308–18.
   Google Scholar
• Wang J, Dudman NPB, Wilcken DEL. Effect of homocysteine and related compounds on prosta-cyclin production by cultured human vascular endothelial cells. Thromb Hemostas 1993; 70: 1047–52.
   Google Scholar